Cerebrospinal fluid IL-6, TNF-α and MCP-1 in children with acute lymphoblastic leukaemia during chemotherapy

Area of Science:

• Neuroscience
• Immunology
• Pediatric Oncology

Background:

• Acute lymphoblastic leukaemia (ALL) is a common childhood cancer.
• Chemotherapy is the standard treatment for ALL.
• Potential neurotoxic effects of chemotherapy are a concern in pediatric patients.

Purpose of the Study:

• To investigate changes in cerebrospinal fluid (CSF) cytokine levels during chemotherapy for ALL in children.
• To assess the relationship between CSF cytokine profiles and potential subclinical inflammation or neurotoxicity.

Main Methods:

• Analysis of CSF samples from 12 pediatric ALL patients.
• Measurement of cytokine levels including interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), and tumour necrosis factor-α (TNF-α) at diagnosis, after induction, during consolidation, and post-therapy.
• Comparison of cytokine levels across different treatment phases.

Main Results:

• Significant increases in IL-6 and MCP-1 were observed after induction treatment.
• Elevated levels of IL-6, TNF-α, and MCP-1 were found during the consolidation phase compared to diagnosis.
• No significant differences in CSF cytokine levels were noted after completion of therapy.

Conclusions:

• Standard ALL chemotherapy may induce subclinical inflammation in the central nervous system.
• Elevated CSF cytokines suggest a potential for chemotherapy-induced neurotoxicity in pediatric ALL patients.
• Further research is needed to elucidate the long-term neurological consequences.